Despite the relative success of immunotherapy over chemotherapy witnessed in the past decade, PD-(L)1 blockade was far from perfect to induce durable immune responses for every patient from the total unselected NSCLC population, even within the PD-L1-positive stratum, calling for an exigent need of reliable immunotherapeutic predictors to promote precision medicine. Here, CD274 is linked to non-small cell lung carcinoma.